07.19.18
Genesis Drug Discovery & Development (GD3) the contract research organization of Genesis Biotechnology Group, has announced the appointment of Olesia Buiakova, M.D., Ph.D., the current chief scientific officer of Invivotek, as its new chief scientific officer.
Dr. Buiakova began her career with GBG as the Vice President of Biology for Invivotek in 2013. Later that year, she transitioned into her current role as chief scientific officer, where she oversaw a multidisciplinary pre-clinical contract research team and was responsible for establishing and managing pre-clinical animal research programs for several big Pharma and biotech companies, including in vivo pharmacology programs for sister companies at GBG.
In this capacity, as an expansion of Dr. Buiakova's current role, she will be responsible for managing the entire integrated GD3 portfolio of drug discovery services from target validation and assay development to identification of clinical candidates. Dr. Buiakova will provide leadership, oversight and coordination for the development and management of new preclinical drug discovery platforms in oncology, immunology, metabolic and ocular diseases.
Dr. Buiakova began her career with GBG as the Vice President of Biology for Invivotek in 2013. Later that year, she transitioned into her current role as chief scientific officer, where she oversaw a multidisciplinary pre-clinical contract research team and was responsible for establishing and managing pre-clinical animal research programs for several big Pharma and biotech companies, including in vivo pharmacology programs for sister companies at GBG.
Dr. Buiakova has over 20 years of experience in the pharmaceutical, biotechnology and CRO industries.
"We are grateful to Olesia for her previous scientific leadership, and look forward to continuing to work closely with her in her newly expanded role as an advisor and collaborative partner to pharmaceutical, sponsor and academic organizations" said Dr. Eli Mordechai, chief executive officer of Genesis Biotechnology Group.